| Not Yet Recruiting | REal World MAIA UK OutcomEs NCT07532473 | The Royal Wolverhampton Hospitals NHS Trust | — |
| Not Yet Recruiting | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors NCT07297160 | Baylor College of Medicine | Phase 1 |
| Not Yet Recruiting | Evaluation of Skin Tests in Biotherapy Allergies NCT06971848 | University Hospital, Angers | N/A |
| Recruiting | HEME Home Transfusion Program NCT06487247 | Dana-Farber Cancer Institute | N/A |
| Recruiting | Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy NCT07390071 | University of Utah | N/A |
| Recruiting | A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma NCT07106671 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties NCT07052916 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma NCT06947083 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) NCT07202078 | Monash University | Phase 2 / Phase 3 |
| Recruiting | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension NCT07202091 | Monash University | Phase 2 / Phase 3 |
| Recruiting | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) NCT07202052 | Monash University | Phase 2 / Phase 3 |
| Recruiting | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) NCT07202065 | Monash University | Phase 2 / Phase 3 |
| Recruiting | Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care NCT05745285 | University of Miami | N/A |
| Active Not Recruiting | Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia NCT06944119 | Tel-Aviv Sourasky Medical Center | — |
| Recruiting | Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM NCT06518551 | Omar Nadeem, MD | Phase 1 / Phase 2 |
| Not Yet Recruiting | PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications NCT06450821 | University of Leeds | N/A |
| Recruiting | PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab) NCT06430736 | Insel Gruppe AG, University Hospital Bern | Phase 2 |
| Withdrawn | Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT NCT04685525 | Case Comprehensive Cancer Center | N/A |
| Withdrawn | Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma NCT03591614 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Recruiting | Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor f NCT06066359 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | Assessing the Relationship Between Hypoxia and the Immune Environment in Myeloma Patients (CHIME) NCT06007989 | The Christie NHS Foundation Trust | — |
| Active Not Recruiting | Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Tr NCT05889221 | Poitiers University Hospital | N/A |
| Recruiting | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma NCT05651932 | K36 Therapeutics, Inc. | Phase 1 |
| Completed | Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunot NCT05763563 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Recruiting | Pilot Imaging Study of Leukemia NCT03633955 | University of Oklahoma | Phase 1 |
| Recruiting | Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation NCT04935684 | University Hospital, Clermont-Ferrand | Phase 2 |
| Completed | Non-invasive MRD Assessment in Multiple Myeloma NCT05625971 | Rajshekhar Chakraborty, MD | — |
| Recruiting | Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma NCT03832127 | Nantes University Hospital | Phase 1 |
| Recruiting | European Rare Blood Disorders Platform (ENROL) NCT06250595 | Hospital Universitari Vall d'Hebron Research Institute | — |
| Unknown | Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic NCT05154474 | Weprom | — |
| Not Yet Recruiting | Dual-Energy Computed Tomography for Improving Imaging Assessment of Multiple Myeloma NCT05353907 | Guy's and St Thomas' NHS Foundation Trust | — |
| Recruiting | A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the T NCT05055063 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT NCT04862676 | University of Rochester | EARLY_Phase 1 |
| Terminated | Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refract NCT04843579 | Weill Medical College of Cornell University | Phase 2 |
| Completed | A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. NCT05228470 | Pfizer | Phase 2 |
| Unknown | Understanding Patterns of Fatigue in Health and Disease NCT05622669 | University of Aberdeen | — |
| Completed | Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma NCT04999085 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Withdrawn | SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies NCT05393999 | Imperial College Healthcare NHS Trust | Phase 2 |
| Unknown | Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignanc NCT05203809 | Malaghan Institute of Medical Research | — |
| Completed | Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy NCT05065866 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | FT576 in Subjects With Multiple Myeloma NCT05182073 | Fate Therapeutics | Phase 1 |
| Recruiting | Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies NCT05528887 | The Affiliated People's Hospital of Ningbo University | Phase 1 |
| Active Not Recruiting | Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib NCT04751877 | Poitiers University Hospital | Phase 3 |
| Completed | Removing Transfusion Dependence as a Barrier to Hospice Enrollment NCT05063591 | Adam Olszewski | N/A |
| Active Not Recruiting | Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple My NCT04680468 | University of Pennsylvania | Phase 2 |
| Completed | Evaluation of the Success of Prophylactic Enteral Nutrition in Therapeutic Intensification With Autograft of A NCT04703985 | University Hospital, Bordeaux | — |
| Completed | Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT NCT04194840 | Case Comprehensive Cancer Center | N/A |
| Completed | Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Com NCT04952766 | Centre Hospitalier Régional d'Orléans | Phase 4 |
| Unknown | Feasibility of an Adapted Physical Activity Program for Patients Treated With an Autograft (APA²) NCT04320420 | Weprom | N/A |
| Terminated | FT538 in Subjects With Advanced Hematologic Malignancies NCT04614636 | Fate Therapeutics | Phase 1 |
| Unknown | VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma NCT03641456 | Sun Yat-sen University | Phase 2 |
| Recruiting | A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment NCT04268199 | AHS Cancer Control Alberta | Phase 2 |
| Unknown | Cardiovascular Complications of Carfilzomib NCT04407858 | European Georges Pompidou Hospital | — |
| Completed | Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation NCT06892119 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 1 |
| Unknown | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation NCT03836690 | University College, London | Phase 1 |
| Unknown | Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple NCT03695744 | Singapore General Hospital | Phase 2 |
| Terminated | PROactive Evaluation of Function to Avoid CardioToxicity NCT03862131 | Washington University School of Medicine | Phase 2 |
| Active Not Recruiting | Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma NCT03500445 | University of Chicago | Phase 2 |
| Unknown | Vascular Functions in Myeloma Patients During Anti-tumor Therapy NCT03776331 | University Hospital, Essen | — |
| Terminated | MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the Required Analysis? NCT03618212 | Centre Hospitalier Universitaire de Nīmes | — |
| Unknown | Place of the Hevylite Test in the Evaluation of MRD in Myeloma NCT03702088 | University Hospital, Montpellier | — |
| Completed | A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multip NCT07206810 | The First Affiliated Hospital of Soochow University | — |
| Unknown | Machine Learning in Myeloma Response NCT03574454 | Royal Marsden NHS Foundation Trust | N/A |
| Completed | Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Tra NCT03398200 | Omar Aljitawi | Phase 2 |
| Completed | The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Los NCT03951220 | Oxford University Hospitals NHS Trust | — |
| Active Not Recruiting | Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. NCT03314636 | Oslo University Hospital | Phase 2 |
| Completed | Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide NCT03184194 | Amsterdam UMC, location VUmc | Phase 2 |
| Unknown | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tu NCT03302403 | Kang YU | N/A |
| Unknown | Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transpl NCT03373526 | Daniel Godoy Martinez | N/A |
| Completed | Pedometer Activity Monitoring After ASCT NCT03238599 | Insel Gruppe AG, University Hospital Bern | Phase 2 |
| Unknown | WB-EMS and Nutrition in Patients With Hematological Malignancies NCT03556748 | University of Erlangen-Nürnberg Medical School | N/A |
| Recruiting | Liquid Biopsy Evaluation and Repository Development at Princess Margaret NCT03702309 | University Health Network, Toronto | — |
| Unknown | Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation NCT03244930 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
| Recruiting | Bergamo Lymphoid Cancer Registry NCT03131531 | A.O. Ospedale Papa Giovanni XXIII | — |
| Completed | Mobile Health Device Study for Myeloma Patients NCT03006315 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous St NCT03135925 | Sheffield Teaching Hospitals NHS Foundation Trust | N/A |
| Terminated | Positron Emission Tomography (PET) Imaging Studies With NIS Reporter NCT02907073 | Mayo Clinic | Phase 1 / Phase 2 |
| Unknown | Changing Over Time of Ascorbic Acid After Chemotherapy NCT02931942 | Maastricht University Medical Center | — |
| Terminated | Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed NCT02579824 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | PET Imaging of Subjects Using 124I-PU-AD NCT03371420 | Samus Therapeutics, Inc. | EARLY_Phase 1 |
| Completed | The Value of Systematic Biopsies During Vertebroplasty for the Treatment of Osteoporotic Vertebral Fractures NCT06153576 | Centre Hospitalier Universitaire de Nice | — |
| Completed | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis NCT02593123 | Virginia Commonwealth University | Phase 2 |
| Completed | Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplanta NCT02598752 | Memorial Sloan Kettering Cancer Center | — |
| Active Not Recruiting | Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma NCT02542657 | Joseph Tuscano | Phase 1 / Phase 2 |
| Completed | African American Cancer Clinical Trial Decisions: Testing Tailored Messages NCT02356549 | Virginia Commonwealth University | N/A |
| Completed | Imageguided Theranostics in Multiple Myeloma NCT02403102 | Institute of Cancer Research, United Kingdom | — |
| Completed | Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma NCT02188537 | Swiss Cancer Institute | Phase 2 |
| Withdrawn | Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant i NCT02114502 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With NCT02066454 | University Hospital, Grenoble | Phase 3 |
| Completed | Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma NCT01861340 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Unknown | Cryotherapy Against Oral Mucositis After High-dose Melphalan NCT03704597 | Sahlgrenska University Hospital | N/A |
| Terminated | Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) NCT01927718 | M.D. Anderson Cancer Center | N/A |
| Terminated | Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis NCT01807286 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene NCT01875237 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma NCT02027220 | Second Affiliated Hospital of Soochow University | Phase 2 |
| Terminated | Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma NCT01985477 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT NCT01885897 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Completed | Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant NCT01904175 | Duke University | — |
| Completed | PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative NCT01916135 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma NCT01793051 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagn NCT01440582 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) NCT01531998 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With A NCT00943319 | University of Chicago | Phase 1 / Phase 2 |
| Terminated | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells NCT01624701 | Singapore General Hospital | Phase 1 / Phase 2 |
| Terminated | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives NCT01532635 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Terminated | Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) NCT01518153 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Testing a Spanish Version of a Patient Toxicity Questionnaire NCT01517152 | National Cancer Institute (NCI) | — |
| Completed | Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide NCT01432600 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Unknown | Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers NCT01240525 | University College, London | Phase 2 |
| Completed | A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen f NCT01413178 | M.D. Anderson Cancer Center | Phase 3 |
| Completed | Stem Cell Transplantation for Patients With Multiple Myeloma NCT01526096 | University of Chicago | Phase 1 |
| Completed | Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine NCT01396200 | Abramson Cancer Center at Penn Medicine | EARLY_Phase 1 |
| Completed | Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma NCT01245673 | University of Pennsylvania | Phase 2 |
| Terminated | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps NCT01350258 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Withdrawn | Phase II Study of Simvastatin for Relapsed/Refractory Myeloma NCT01332617 | University of Louisville | Phase 2 |
| Terminated | A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma NCT01302366 | NYU Langone Health | Phase 2 |
| Completed | Prevention of Treatment Induced Neuropathy in Multiple Myeloma NCT01283997 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study NCT01269593 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Completed | High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myel NCT01237951 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy NCT01543100 | Rennes University Hospital | N/A |
| Terminated | A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma NCT01248455 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up t NCT01191060 | University Hospital, Toulouse | Phase 3 |
| Completed | Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYS NCT01279694 | Nantes University Hospital | Phase 1 / Phase 2 |
| Terminated | Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Ac NCT01174082 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma NCT01220375 | Insel Gruppe AG, University Hospital Bern | Phase 2 |
| Completed | Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection NCT01095757 | Emory University | Phase 2 |
| Completed | Lenalidomide and High-Dose Melphalan NCT01079936 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Chemotherapy-Induced Peripheral Neuropathy Survey NCT01016028 | M.D. Anderson Cancer Center | — |
| Terminated | Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients NCT00983346 | University of Utah | Phase 2 |
| Completed | Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexame NCT00907452 | Intergroupe Francophone du Myelome | N/A |
| Active Not Recruiting | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL NCT00881920 | Baylor College of Medicine | Phase 1 |
| Completed | Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma NCT00698776 | Yale University | Phase 1 |
| Completed | Acupuncture for Chemo-Induced Peripheral Neuropathy NCT00891618 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy NCT00871013 | University of Arkansas | Phase 2 |
| Completed | Prospective Observational Study on Plerixafor After Chemotherapy NCT01700608 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Completed | Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide NCT00800839 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma NCT00794261 | Centre Leon Berard | Phase 2 |
| Terminated | Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patie NCT01116128 | Fondazione EMN Italy Onlus | Phase 2 |
| Completed | Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant NCT00597714 | David Rizzieri, MD | Phase 2 |
| Completed | Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma NCT01042704 | Robert Redner, MD | Phase 1 |
| Terminated | Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignanc NCT00473551 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Bevacizumab and Bortezomib in Patients With Advanced Malignancy NCT00428545 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple M NCT00439465 | Dartmouth-Hitchcock Medical Center | Phase 2 |
| Completed | Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Tr NCT00466674 | Hospices Civils de Lyon | Phase 2 |
| Completed | Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies NCT00410982 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Long-Term Follow Up Study for AMD3100 Patients NCT00476294 | M.D. Anderson Cancer Center | — |
| Completed | Maintenance Therapy Using Lenalidomide in Myeloma NCT00430365 | University Hospital, Toulouse | Phase 3 |
| Completed | Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients NCT00469209 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma NCT00242827 | Cephalon | Phase 2 |
| Completed | Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions NCT00660166 | Tufts Medical Center | Phase 1 |
| Completed | Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants NCT00606437 | Duke University | Phase 1 |
| Completed | Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) NCT00361140 | H. Lee Moffitt Cancer Center and Research Institute | Phase 4 |
| Completed | Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath NCT00578942 | David Rizzieri, MD | Phase 2 |
| Completed | Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies NCT00990717 | University Health Network, Toronto | Phase 1 |
| Terminated | Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malig NCT00943293 | University of Chicago | Phase 1 |
| Completed | Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath NCT00580034 | David Rizzieri, MD | Phase 2 |
| Completed | TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma NCT01039025 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy NCT01521611 | University Hospital Southampton NHS Foundation Trust | Phase 1 / Phase 2 |
| Completed | Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood NCT00070616 | Swedish Orphan Biovitrum | Phase 1 |
| Completed | Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patien NCT00195533 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and De NCT00344422 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 |
| Completed | Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer Th NCT00005988 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System NCT00001582 | National Cancer Institute (NCI) | — |
| Unknown | Atorvastatin in Myeloma NCT00164086 | Bayside Health | Phase 1 |